fludarabine has been researched along with 2019 Novel Coronavirus Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ata, O; Inci, TG; Kocer, S; Mutlu, O; Sariyer, E; Turgut-Balik, D; Ugurel, E; Ugurel, OM | 1 |
| Campbell, TB; Jagannath, S; Madduri, D; Neumann, F; Parekh, S; Petrocca, F | 1 |
| Bai, S; Cai, Z; Gong, J; Huang, H; Huang, T; Peng, Y; Xiong, G; Xiu, H; Zhang, G; Zhang, S | 1 |
3 other study(ies) available for fludarabine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13).
Topics: Adenosine Monophosphate; Amino Acid Sequence; Betacoronavirus; Binding Sites; Computer Simulation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; Enzyme Inhibitors; Folic Acid; Genome, Viral; Glucosides; Humans; Methyltransferases; Molecular Docking Simulation; Mutation; Pandemics; Pneumonia, Viral; RNA Helicases; SARS-CoV-2; Stilbenes; Vidarabine; Viral Nonstructural Proteins | 2020 |
Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Topics: Antibodies, Viral; B-Cell Maturation Antigen; Cough; COVID-19; COVID-19 Nucleic Acid Testing; COVID-19 Serological Testing; Cyclophosphamide; Disease Progression; Fever; Hospitalization; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; Male; Middle Aged; Multiple Myeloma; Receptors, Chimeric Antigen; SARS-CoV-2; Vidarabine | 2021 |
Fludarabine inhibits type I interferon-induced expression of the SARS-CoV-2 receptor angiotensin-converting enzyme 2.
Topics: A549 Cells; Angiotensin-Converting Enzyme 2; Antiviral Agents; Binding Sites; COVID-19; COVID-19 Drug Treatment; Enzyme Induction; HEK293 Cells; HeLa Cells; Humans; Interferon Type I; Phosphorylation; Promoter Regions, Genetic; Receptors, Virus; STAT1 Transcription Factor; Vidarabine | 2021 |